Skip to main content

The 2013 TechAssure Risk Survey highlights the challenges in regulatory and legislative risks for biopharmaceuticals and life science firms.

The Biopharmaceuticals and life sciences sector was also included in the survey. Based on the survey and our research and experience we identified the top risk concerns for firms operating in the sector. The top three risk factors were risk of damage to reputation, brand, and image, potential changes in the corporate governance, regulatory, and legislative environment, and failure to access capital in that order. Our research has also found that increased competition in the global scene, risk of losing intellectual property, risks associated with the supply chain and inability to manage risks with partners and strategic alliances are among the top risk factors for concern in the Biopharmaceuticals and life sciences sector. Other top ranking risks are associated with network, privacy, and security, inability to innovate new products and services, and risks of delays and interruptions in R&D.

To retrieve a full copy of the summary of the 2013 TechAssure Association Risk Survey, please contact a TechAssure member.

Leave a Reply